Evan Pisick

2.1k total citations
35 papers, 1.7k citations indexed

About

Evan Pisick is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Evan Pisick has authored 35 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 16 papers in Oncology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Evan Pisick's work include Chronic Myeloid Leukemia Treatments (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Research Studies (5 papers). Evan Pisick is often cited by papers focused on Chronic Myeloid Leukemia Treatments (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Research Studies (5 papers). Evan Pisick collaborates with scholars based in United States, Brazil and United Kingdom. Evan Pisick's co-authors include Ravi Salgia, Jian‐Liang Li, James D. Griffin, Martin Sattler, Lan Bo Chen, N. Uemura, Su Hao Lo, Beatrice Brunkhorst, Kanteti V. Prasad and Arthur T. Skarin and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Evan Pisick

29 papers receiving 1.7k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Evan Pisick 797 620 484 427 385 35 1.7k
L Bergui 735 0.9× 832 1.3× 246 0.5× 573 1.3× 890 2.3× 53 2.3k
Todd Hembrough 942 1.2× 398 0.6× 117 0.2× 880 2.1× 232 0.6× 71 2.3k
Teresa K. Kimlinger 939 1.2× 817 1.3× 76 0.2× 716 1.7× 441 1.1× 56 2.1k
Sylvie Freeman 1.5k 1.9× 2.0k 3.1× 192 0.4× 535 1.3× 490 1.3× 73 3.3k
A Strife 1.2k 1.5× 1.3k 2.1× 123 0.3× 544 1.3× 780 2.0× 59 2.7k
Mark B. Meads 771 1.0× 441 0.7× 103 0.2× 753 1.8× 148 0.4× 36 1.6k
Julie C. Lively 1.3k 1.7× 212 0.3× 1.0k 2.1× 455 1.1× 67 0.2× 8 2.0k
Helena Kempski 747 0.9× 820 1.3× 87 0.2× 389 0.9× 204 0.5× 42 2.0k
Michelle Kuhne 933 1.2× 186 0.3× 133 0.3× 788 1.8× 243 0.6× 35 2.2k
N Huang 501 0.6× 774 1.2× 149 0.3× 451 1.1× 209 0.5× 15 1.3k

Countries citing papers authored by Evan Pisick

Since Specialization
Citations

This map shows the geographic impact of Evan Pisick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan Pisick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan Pisick more than expected).

Fields of papers citing papers by Evan Pisick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan Pisick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan Pisick. The network helps show where Evan Pisick may publish in the future.

Co-authorship network of co-authors of Evan Pisick

This figure shows the co-authorship network connecting the top 25 collaborators of Evan Pisick. A scholar is included among the top collaborators of Evan Pisick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evan Pisick. Evan Pisick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hosein, Peter J., Michael Rothe, Elizabeth Garrett‐Mayer, et al.. (2025). Nivolumab plus ipilimumab (N+I) in patients (pts) with pancreatic cancer (PC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 43(4_suppl). 715–715. 1 indexed citations
2.
Mambetsariev, Isa, et al.. (2025). Current paradigm of EGFR in non-small cell lung cancer: A long way forward. Med. 6(9). 100803–100803.
3.
Sahai, Vaibhav, Michael Rothe, Pam K. Mangat, et al.. (2024). Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology. 8(8). e2300527–e2300527.
4.
Becker, Simone, et al.. (2023). Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report. JTO Clinical and Research Reports. 5(1). 100625–100625. 1 indexed citations
5.
6.
Sattler, Martin, Isa Mambetsariev, Nagarajan Vaidehi, et al.. (2023). A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine. Journal of Clinical Medicine. 12(5). 1936–1936. 9 indexed citations
7.
Kulkarni, Prakash, S. Bhattacharya, Arin Nam, et al.. (2023). A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer. Journal of Clinical Medicine. 12(2). 599–599. 13 indexed citations
8.
Garg, Pankaj, Atish Mohanty, Prakash Kulkarni, et al.. (2023). Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1878(6). 189026–189026. 20 indexed citations
9.
Rothe, Michael, Pam K. Mangat, Elizabeth Garrett‐Mayer, et al.. (2023). Abstract CT231: Temsirolimus (T) in patients (pts) with solid tumors with PTEN mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cancer Research. 83(8_Supplement). CT231–CT231.
10.
Calfa, Carmen, Michael Rothe, Gordan Srkalović, et al.. (2023). Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 41(16_suppl). 3117–3117.
11.
Pisick, Evan & Ravi Salgia. (2005). Molecular Biology of Malignant Mesothelioma: A Review. Hematology/Oncology Clinics of North America. 19(6). 997–1023. 13 indexed citations
12.
Pisick, Evan, Simha Jagadeesh, & Ravi Salgia. (2003). Small cell lung cancer: from molecular biology to novel therapeutics. PubMed. 3(6). 305–318. 12 indexed citations
13.
Rubin, Brian P., et al.. (2001). Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. European Journal of Cancer Prevention. 10(1). 77–82. 75 indexed citations
14.
Salgia, Ravi, Jian‐Liang Li, Youbin Wang, et al.. (1999). Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene. 18(1). 67–77. 78 indexed citations
15.
Sattler, Martin, Ravi Salgia, Gautam Shrikhande, et al.. (1997). Steel Factor Induces Tyrosine Phosphorylation of CRKL and Binding of CRKL to a Complex Containing c-Kit, Phosphatidylinositol 3-Kinase, and p120CBL. Journal of Biological Chemistry. 272(15). 10248–10253. 101 indexed citations
16.
Salgia, Ravi, Jian‐Liang Li, Warren S. Pear, et al.. (1997). BCR/ABL induces multiple abnormalities of cytoskeletal function.. Journal of Clinical Investigation. 100(1). 46–57. 146 indexed citations
17.
Uemura, Naomi, et al.. (1997). The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins. Leukemia. 11(3). 376–385. 37 indexed citations
18.
Salgia, Ravi, Evan Pisick, Martin Sattler, et al.. (1996). p130CAS Forms a Signaling Complex with the Adapter Protein CRKL in Hematopoietic Cells Transformed by the BCR/ABL Oncogene. Journal of Biological Chemistry. 271(41). 25198–25203. 105 indexed citations
19.
Salgia, Ravi, N. Uemura, Keiko Okuda, et al.. (1995). CRKL Links p210BCR/ABL with Paxillin in Chronic Myelogenous Leukemia Cells. Journal of Biological Chemistry. 270(49). 29145–29150. 113 indexed citations
20.
Salgia, Ravi, Jian‐Liang Li, Su Hao Lo, et al.. (1995). Molecular Cloning Of Human Paxillin, a Focal Adhesion Protein Phosphorylated by P210BCR/ABL. Journal of Biological Chemistry. 270(10). 5039–5047. 246 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L Bergui Breakdown of academic impact, for papers by Todd Hembrough Breakdown of academic impact, for papers by Teresa K. Kimlinger Breakdown of academic impact, for papers by Sylvie Freeman Breakdown of academic impact, for papers by A Strife Breakdown of academic impact, for papers by Mark B. Meads Breakdown of academic impact, for papers by Julie C. Lively Breakdown of academic impact, for papers by Helena Kempski Breakdown of academic impact, for papers by Michelle Kuhne Breakdown of academic impact, for papers by N Huang
Rankless by CCL
2026